Clinical Trials

NCT Number: NCT04331535 Phase: Not Applicable Trial Summary: This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Boston VA Research Institute, Inc. Acronym: GenoVA

NCT Number: NCT04585750 Phase: Phase 1|Phase 2 Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations Clinicaltrials.gov Trial Sponsor(s): PMV Pharmaceuticals, Inc Acronym:

NCT Number: NCT06136650 Phase: PHASE3 Trial Summary: The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metast – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Merck Sharp & Dohme LLC Acronym:

NCT Number: NCT05806814 Phase: PHASE1 Trial Summary: Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Oklahoma Acronym: OUSCCEXCITE

NCT Number: NCT04586270 Phase: PHASE1 Trial Summary: The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Taiho Oncology, Inc. Acronym:

NCT Number: NCT05806515 Phase: PHASE2 Trial Summary: This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): SWOG Cancer Research Network Acronym:

NCT Number: NCT05946213 Phase: PHASE3 Trial Summary: This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NRG Oncology Acronym:

NCT Number: NCT06085664 Phase: PHASE1|PHASE2 Trial Summary: To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

NCT Number: NCT06218667 Phase: PHASE1|PHASE2 Trial Summary: The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment t – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT05708950 Phase: Phase 1|Phase 2 Trial Summary: The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors.… – see link above for mo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Kineta Inc. Acronym: